Opportunity
SAM #36C25027Q0113
VA Market Research for Prostate Cancer Genomic Classifier Testing Services
Buyer
VA Network Contracting Office 10
Posted
November 17, 2026
Respond By
November 25, 2026
Identifier
36C25027Q0113
NAICS
621511
The Department of Veterans Affairs is researching providers of prostate cancer genomic classifier testing for the Chalmers P. Wylie VA Ambulatory Center. - Government buyer: Department of Veterans Affairs (VA), Veterans Health Administration; Network Contracting Office 10 (Ohio, Columbus VAAC). - Requested service: Testing of prostate biopsy and/or prostatectomy tissue using a validated genomic analysis platform, with patient-specific reports assessing disease progression, metastasis, and prostate cancer-specific mortality risks to support treatment decisions. - Service capabilities: Electronic ordering and reporting, specimen shipping and logistics, technical and clinical customer support, stated turnaround times, and nationwide service for VA facilities. - Quality and evidence requirements: Testing laboratories must have CLIA certification and CAP accreditation or equivalent. Predictive results must be clinically validated and supported by published evidence, including the maximum validated prediction horizon. - OEMs and vendors: No OEMs or vendors are named in the notice or attachment summaries. Potential providers of comparable services include Veracyte (Decipher Prostate) and Myriad Genetics (Prolaris); these are market alternatives, not identified respondents. - Quantities and part numbers: Not specified. - Opportunity status: Sources sought market research only; it is not a solicitation or commitment to award.
Description
This is a Sources Sought Notice only. It is issued solely for information and planning purposes and does not constitute a solicitation. This notice is issued in accordance with Federal Acquisition Regulation (FAR) Part 10, Market Research. The Department of Veterans Affairs (VA) is conducting market research to identify qualified sources capable of providing prostate cancer genomic classifier testing services. The purpose of this notice is to determine the availability of capable businesses and inform an appropriate acquisition strategy. This notice shall not be construed as a commitment by the Government to issue a solicitation or award a contract. Responses are not offers and cannot be accepted by the Government to form a binding contract. The Government will not reimburse any costs associated with responding to this notice. See attached document for details and response requirements.